The outcome of patients with Hodgkin lymphoma and early relapse after autologous stem cell transplant has improved in recent years

• 全文链接
• 请求原文

作   者：

Bazarbachi, Ali;  Boumendil, Ariane;  Finel, Herve;  Khvedelidze, Irma;  Romejko-Jarosinska, Joanna;  Tanase, Alina;  Akhtar, Saad;  Ben Othman, Tarek;  Ma'koseh, Mohammad;  Afanasyev, Boris;  Cheikh, Jean;  Briones, Javier;  Gulbas, Zafer;  Hamladji, Rose-Marie;  Elverdi, Tugrul;  Blaise, Didier;  Martinez, Carmen;  Alma, Eleonora;  Halaburda, Kazimierz;  Sousa, Aida Botelho;  Glass, Bertram;  Robinson, Steven;  Montoto, Silvia;  Sureda, Anna; 

作者机构：

Hosp Santa Creu & Sant Pau;  King Hussein Canc Ctr;  First State Pavlov Med Univ St Petersburg;  Dept Hematopoiet Stem Cell Transplantat;  Univ Barcelona;  Inst Paoli Calmettes;  Maria Sklodowska Curie Natl Res Inst Oncol;  Inst Hematol & Transfus Med;  Oncol Ctr;  Dept Lymphoid Malignancies;  Hosp St Antoine;  Dept Haemato Oncol;  Clin Hematol & Cellular Therapy Dept;  EBMT LWP Paris Off Hop St Antoine;  Ctr Natl Greffe De La Moelle Osseuse;  European Soc Blood & Marrow Transplantat;  Bristol Oncol Ctr;  Inst Hematol;  Hosp Capuchos;  Hematol Serv;  Fundeni Clin Inst;  Raisa Gorbacheva Mem Res Inst Paediat Oncol;  Helios Clin;  Dept Haematol & Stem Cell Transplantat;  Inst Catala Oncol Hosp;  Univ Cattolica Sacro Cuore;  Ctr Pierre & Marie Curie;  Dept Haematol;  King Faisal Specialist Hosp & Res Ctr;  Istanbul Univ Cerrahpasa;  Inst Hematol & Oncol;  Amer Univ Beirut;  Barts Hlth NHS Trust;  Cerrahpasa Sch Med;  Dept Internal Med;  Anadolu Med Ctr;  Hosp Clin Barcelona; 

关键词：

THERAPY;  BONE-MARROW-TRANSPLANTATION;  PD-1 BLOCKADE;  DISEASE;  BRENTUXIMAB VEDOTIN;  PHASE-II;  HIGH-DOSE CHEMOTHERAPY;  NIVOLUMAB;  FAILURE;  WORKING PARTY; 

期刊名称：

Leukemia: Official journal of the Leukemia Society of America, Leukemia Research Fund, U.K

i s s n：

0887-6924

年卷期：

2022 年 36 卷 6 期

页   码：

1646-1653

页   码：

摘   要：

Hodgkin lymphoma (HL) patients who relapse after autologous-stem-cell- transplantation (auto-SCT) have traditionally had a poor prognosis. We analyzed 1781 adult HL patients who relapsed between 2006 and 2017 after a first auto-SCT. The 4-year overall survival (OS) after relapse continuously increased from 32% for patients relapsing in 2006-2008, to 63% for patients relapsing in 2015-2017 (p = 0.001). The improvement over time was predominantly noted in patients who had an early relapse (within 12 months) after auto-SCT (p = 0.01). On multivariate analysis, patients who relapsed in more recent years and those with a longer interval from transplant to relapse had a better OS, whereas increasing age, poor performance status, bulky disease, extranodal disease and presence of B symptoms at relapse were associated with a worse OS. Brentuximab vedotin (BV), checkpoint inhibitors (CPI) and second transplant (SCT2; 86% allogeneic) were used in 233, 91 and 330 patients respectively. The 4-year OS from BV, CPI, and SCT2 use was 55%, 48% and 55% respectively. In conclusion, the outcome after post-transplant relapse has improved significantly in recent years, particularly in the case of early relapse. These large-scale real-world data can serve as benchmark for future studies in this setting.